^
Association details:
| Biomarker: | ALK G1202del |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Molecular resistance mechanisms of ALK inhibitors and implications for therapeutic management of ALK-rearranged lung cancer patients
Excerpt:
Changes in ALK resistance mutational profile following treatment with the second-generation ALK inhibitors ceritinib (N=23), alectinib (N=17), or brigatinib (N=6) were also examined...Ectopic expression of the EML4–ALK G1202del mutant in Ba/F3 cells suggested that the G1202del ALK mutant confers moderate resistance to ceritinib, alectinib, and brigatinib with crizotinib potency being less affected...Finally, for the 7 patients treated with brigatinib, ALK resistance mutations were observed in 5 of 7 (71%)...
DOI:
10.21037/tcr.2017.03.22
